CIK 0001819133 · Non-accelerated filer<br>Smaller reporting company
Tango Therapeutics, Inc.
Sign in to watch- Ticker
- TNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (857) 320-4900
- Business address
- 201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
- Former names
- BCTG Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,858,086
- in 6 filings, $1.9M under 10b5-1 plans
Net −$1,858,086. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 18 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-11 | Crystal Adam President, R&D | Option exercise 10b5-1 | +5,000 | $2.91 | $15K | 120,743 |
| 2026-11-11 | Crystal Adam President, R&D | Sale 10b5-1 | −5,000 | $25.00 | $125K | 115,743 |
| 2026-11-11 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 308,090 | ||
| 2026-11-02 | Crystal Adam President, R&D | Option exercise 10b5-1 | +5,000 | $2.91 | $15K | 120,743 |
| 2026-11-02 | Crystal Adam President, R&D | Sale 10b5-1 | −3,900 | $22.26 | $87K | 116,843 |
| 2026-11-02 | Crystal Adam President, R&D | Sale 10b5-1 | −1,100 | $22.99 | $25K | 115,743 |
| 2026-11-02 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 313,090 | ||
| 2026-11-02 | Newcomb Jessica Principal Accounting Officer | Sale 10b5-1 | −5,571 | $22.28 | $124K | 53,550 |
| 2026-11-02 | Newcomb Jessica Principal Accounting Officer | Sale 10b5-1 | −1,460 | $22.98 | $34K | 52,090 |
| 2026-10-01 | Crystal Adam President, R&D | Option exercise 10b5-1 | +27,000 | $5.20 | $140K | 142,743 |
| 2026-10-01 | Crystal Adam President, R&D | Sale 10b5-1 | −26,400 | $24.45 | $646K | 116,343 |
| 2026-10-01 | Crystal Adam President, R&D | Sale 10b5-1 | −600 | $25.32 | $15K | 115,743 |
| 2026-10-01 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,000 | 233,040 | ||
| 2026-09-22 | Newcomb Jessica Principal Accounting Officer | Sale 10b5-1 | −700 | $22.80 | $16K | 66,621 |
| 2026-09-22 | Newcomb Jessica Principal Accounting Officer | Sale 10b5-1 | −5,100 | $23.97 | $122K | 61,521 |
| 2026-09-22 | Newcomb Jessica Principal Accounting Officer | Sale 10b5-1 | −2,400 | $25.17 | $60K | 59,121 |
| 2026-09-01 | Crystal Adam President, R&D | Option exercise 10b5-1 | +27,000 | $5.20 | $140K | 142,743 |
| 2026-09-01 | Crystal Adam President, R&D | Sale 10b5-1 | −27,000 | $22.37 | $604K | 115,743 |
| 2026-09-01 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,000 | 260,040 | ||
| 2026-08-03 | Crystal Adam President, R&D | Option exercise 10b5-1 | +27,000 | $5.20 | $140K | 142,743 |
Page 1 of 11 · 211 trades